Scientific publications
Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer
Villar Álvarez F (1), Muguruza Trueba I (2), Belda Sanchis J (3), Molins López-Rodó L (4), Rodríguez Suárez PM (5), Sánchez de Cos Escuín J (6), Barreiro E (7), Borrego Pintado MH (8), Disdier Vicente C (9), Flandes Aldeyturriaga J (10), Gámez García P (11), Garrido López P (12), León Atance P (13), Izquierdo Elena JM (14), Novoa Valentín NM (15), Rivas de Andrés JJ (16), Royo Crespo Í (16), Salvatierra Velázquez Á (17), Seijo Maceiras LM (18), Solano Reina S (19), Aguiar Bujanda D 20, Avila Martínez RJ (11), de Granda Orive JI (21), de Higes Martinez E (22), Diaz-Hellín Gude V (11), Embún Flor R (16), Freixinet Gilart JL (5), García Jiménez MD (13), Hermoso Alarza F (11), Hernández Sarmiento S (20), Honguero Martínez AF (13), Jimenez Ruiz CA (23), López Sanz I (14), Mariscal de Alba A (11), Martínez Vallina P (16), Menal Muñoz P (24), Mezquita Pérez L (1)2, Olmedo García ME (12), Rombolá CA (13), San Miguel Arregui I (25), de Valle Somiedo Gutiérrez M (10), Triviño Ramírez AI (13), Trujillo Reyes JC (3), Vallejo C (26), Vaquero Lozano P (19), Varela Simó G (15), Zulueta JJ (27).
ABSTRACT
The Thoracic Surgery and Thoracic Oncology groups of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) have backed the publication of a handbook on recommendations for the diagnosis and treatment of non-small cell lung cancer.
Due to the high incidence and mortality of this disease, the best scientific evidence must be constantly updated and made available for consultation by healthcare professionals.
To draw up these recommendations, we called on a wide-ranging group of experts from the different specialties, who have prepared a comprehensive review, divided into 4 main sections.
The first addresses disease prevention and screening, including risk factors, the role of smoking cessation, and screening programs for early diagnosis.
The second section analyzes clinical presentation, imaging studies, and surgical risk, including cardiological risk and the evaluation of respiratory function.
The third section addresses cytohistological confirmation and staging studies, and scrutinizes the TNM and histological classifications, non-invasive and minimally invasive sampling methods, and surgical techniques for diagnosis and staging.
The fourth and final section looks at different therapeutic aspects, such as the role of surgery, chemotherapy, radiation therapy, a multidisciplinary approach according to disease stage, and other specifically targeted treatments, concluding with recommendations on the follow-up of lung cancer patients and surgical and endoscopic palliative interventions in advanced stages.
CITATION Arch Bronconeumol. 2016 May 26. pii: S0300-2896(16)30016-3. doi: 10.1016/j.arbres.2016.02.016